New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...
Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...
The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...
NICE has approved another epilepsy treatment for Lennox–Gastaut syndrome. Fenfluramine can be used as an add-on to other ...
News Medical on MSN4d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
MONTCO.Today on MSN1d
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep DisorderPlymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...
The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback